Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant

DYADIC INTERNATIONAL INC

Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.
Reports $250,000 milestone payment for second non-animal dairy enzyme program.
Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.
Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.
Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.